Details

Autor(en) / Beteiligte

• Uguen, Arnaud

Titel

Cost-effectiveness of biomarker testing for treatment choices in advanced non-small cell lung carcinoma: impact of diagnostic strategies and their turnaround times

Ist Teil von

• The European respiratory journal, 2018-06, Vol.51 (6), p.1800602-1800602

Ort / Verlag

England: European Respiratory Society Journals Ltd

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Lung cancer remains the main cause of cancer death in the world, not only because of its high frequency but also because it is often diagnosed at poor-prognosis, advanced stages. A better understanding of the molecular mechanisms involved in tumour initiation and progression has permitted to develop new targeted therapies and immunotherapies and molecular testing has now become a standard in care for patients with advanced non-small cell lung cancer (NSCLC). In the era of personalised medicine, the study by Loubière et al. [1] demonstrated that molecular testing prior to treatment initiation is a cost-effective approach in the management of patients with advanced NSCLC. Beside the calculation of global incremental cost-effectiveness ratios, a major interesting point of the study by Loubièère et al. [1] is their proposal of a step-by-step evaluation of the costs related to diagnosis, treatments and inpatient care. In this correspondence, I intend to further comment on the diagnosis-related costs and their potential impact on the total costs.